Dal-Hee Min

Dr. Dal-Hee Min is currently a Professor at Seoul National University, and CTO and co-founder of Lemonex Inc. She received her Ph.D in Chemistry from the University of Chicago and conducted post-doctoral research at MIT.

She focuses on drug delivery systems with a collective understanding of nano-surface chemistry and diverse biomedical applications of nanomaterials, including cancer immunotherapy, mRNA vaccines, and gene therapies towards safe, effective, and thermostable nanobiomedicines.

Lemonex Inc, where she serves as CTO, performs commercial development of nanobiomedicines based on a chemically well-defined drug delivery system, DegradaBALL. Lemonex signed a strategic partnership with CEPI (Coalition for Epidemic Preparedness Innovation) and successfully conducted a Phase I clinical trial of the mRNA-DegradaBALL vaccine for Disease X, confirming excellent safety and tolerability. With confirmed safety in humans and strong scientific data and papers supporting the therapeutic effects of cancer immunotherapy and vaccines, Lemonex is aiming to broaden global partnerships as a DDS provider for mRNA, siRNA, peptide, and protein APIs.

She received various prestigious awards, including ‘The KCS-Wiley Young Chemist Award’, ‘The Korea L’Oreal UNESCO Fellowship Award for Women in Science’, ‘Commendation from the Minister of SMEs and Startups (Korean Government)’ and ‘The Order of Science and Technology Merit (Do-Yak Medal, Korean Government)’.

She is actively involved in many global activities. For highlighted activities, she gave invited talks at the World Economic Forum in 2018 where she introduced DDS technology-‘Miniaturizing Biotechnology’. She also gave invited talks at the mRNA health conferences, PODD, JP Morgan, BIO USA, GRC, etc.